Navigation Links
Jazz Pharmaceuticals Pays Accrued Interest Under Senior Secured Notes
Date:7/7/2009

ard-looking statements, including statements related to Jazz Pharmaceuticals' belief that it has cured all material defaults under the agreement governing the notes and that it will be able to comply with the agreement on an ongoing basis. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and belief and inherently involve significant risks and uncertainties. Jazz Pharmaceuticals' actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that the holders of the notes may not agree that all material defaults under the agreement governing the notes have been cured, risks that the holders of the notes may attempt to accelerate the notes and declare all of the notes to be immediately due and payable, in which event Jazz Pharmaceuticals could be required to seek protection under the provisions of the U.S. Bankruptcy Code, and risks related to Jazz Pharmaceuticals' future financial performance and financial position. These and other risk factors are discussed under "Risk Factors" in the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on May 7, 2009 and in Item 8.01 of a Current Report on Form 8-K to be filed by Jazz Pharmaceuticals with the Securities and Exchange Commission on July 7, 2009. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

    Contact at Jazz Pharmaceuticals:
    Willie Quinn, Executive Director, Corporate Development of Jazz
    Pharmaceuticals, Inc.
    +1-650-496-2800
    investorinfo@jazzpharmaceuticals.com

    BCC Partners on behalf of Jazz Pharmaceuticals
'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Jazz Pharmaceuticals Completes $7 Million Private Placement
2. Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan
3. ADVENTRX Pharmaceuticals Announces Closing of Financing
4. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a Bispecific Antibody to ErbB2/3
5. Endo Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
6. Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial
7. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
8. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
9. Lotus Pharmaceuticals, Inc. Again Awarded GSP Certification
10. Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm
11. Biostar Pharmaceuticals, Inc. Begins Construction of Raw Material Processing Facility of the Herbal Plantation Base
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... According to the Living With KP book ... guide that features a series of tips and advice ... pilaris). This guide consists of 14 chapters including:, ...     Chapter 2: What Cause KP? ,     Chapter ... ,     Chapter 4: Keratosis Pilaris Treatment , ...
(Date:7/12/2014)... 13, 2014 Recently, Fadhits.com, a well-known wedding ... elegant long graduation dresses to its product line. ... its loyal clients. It wants to bring more benefits for ... now offered at discounted prices, up to 72% off. , ... always working hard. Its online shop is a good place ...
(Date:7/12/2014)... July 12, 2014 The Passenger Information ... in 2013 to $20,341.36 million by 2019, at an ... and 2019. , The public transport infrastructure in North ... also available in almost every corner of the region. ... interest of public transport service providers are driving the ...
(Date:7/12/2014)... The report, "Phthalic Anhydride and Derivatives ... Application & Geography – Trends & Forecast to 2018," ... forecasting of market volume and value. The report also ... The market of phthalic anhydride is projected to grow ... million by 2018, with a CAGR of 5.24% from ...
(Date:7/12/2014)... TX (PRWEB) July 12, 2014 ... market research report, ‘cognitive assessment and training’ ... to monitor, assess, train, or enhance cognitive ... uses such as in dementia screening, clinical ... management, classroom learning, self assessment, brain training, ...
Breaking Medicine News(10 mins):Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 2Health News:Living With KP Book Review Exposes Jennifer Richards' Keratosis Pilaris Guide – Vkool.com 3Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5
... 18 DuPont Group Vice,President Mark P. Vergnano ... 37th Annual Investor Conference today that the Safety ... global demands,for products and services that protect lives, ... uniquely positioned to deliver innovations for safety and,security ...
... be efficiently and inexpensively producing novel pharmaceutical compounds, ... obesity, as well as high-value chemicals, as the ... Buffalo researchers. , In work that could transform ... compounds are produced commercially, the UB researchers are ...
... dated data leave consumers confused, study finds , , TUESDAY, ... information on a hospital,s quality by looking at Web ... or dated data, a new study finds. , In ... produced inconsistent results and used inappropriate or incomplete standards ...
... by opponents,to "assisted suicide," those seeking to make the ... of "assisted suicide,",including a few members of the religious ... sessions -- via a new 1-800 number -- to,help ... "This effort to put a clerical collar on ...
... TRENTON, Mich., Sept. 18 Oakwood Southshore,Medical Center ... "Southshore,Promise," thanks to a generous gift from Anthony ... the downriver hospital., "The Southshore Promise is ... Hughes, division president, Oakwood Southshore,Medical Center. "We are ...
... New National Physician ... Survey, ... campaign visits Washington today to,draw attention to an imminent access to care ... payments,10 percent on January 1, 2008, and physicians are deeply concerned about,the ...
Cached Medicine News:Health News:DuPont Focused on Meeting Global Demands for Greater Safety & Protection 2Health News:Researchers genetically engineer micro-organisms into tiny factories 2Health News:Researchers genetically engineer micro-organisms into tiny factories 3Health News:Hospital Quality Info on Web Can Be Misleading 2Health News:Hospital Quality Info on Web Can Be Misleading 3Health News:$1 Million Gift Boosts Downriver Community 2Health News:Medicare Cuts to Physicians Will Harm Washington Seniors 2
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
(Date:7/10/2014)... , July 10, 2014   LabStyle Innovations ... Solution, today announced the appointment of Professor ... of its Board of Directors. Prof. ... business experience to LabStyle as an entrepreneur, venture ... and corporate governance expert. He currently serves on ...
(Date:1/15/2014)... Corporation (OTC BB: SOTK) today announced sales of  $2,650,000 for ... of $2,202,000 for the prior year period, an increase of ... growth over the preceding quarter,s sales, continuing a trend that ... that experienced sales increases over the prior year were in ...
Breaking Medicine Technology:LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... 24 GeoVax Labs, Inc. (OTC,Bulletin Board: GOVX) ... their candidate AIDS,vaccine failed to provide protection in a ... Merck trial involving high risk volunteers, an equal number ... Data Safety,Monitoring Board recommended that the trial be stopped ...
... 24 Progen Pharmaceuticals,Limited (ASX: PGL; Nasdaq: PGLA) ... of PI-88 in combination with the chemotherapeutic agent,docetaxel ... cancer did not meet,its primary endpoint of significantly ... docetaxel alone. The trial also did not meet ...
Cached Medicine Technology:GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vaccine Trial 2GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vaccine Trial 3GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vaccine Trial 4GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vaccine Trial 5Progen Announces PI-88 Phase 2 Lung Cancer Results 2
... a lightweight, portable console display module. It has ... channels for up to one or two fiber ... alarms for low and high limits for StO2 ... and requires minimal training., ,Sensors of different depths ...
CO 2 SMO-Capnograph/Pulse Oximeter...
... the next generation in pulse oximetry monitoring ... current family of "digital pulse oximeters, MARSpO ... breakthroughs in signal processing. This provides improved ... superior performance during challenging clinical conditions such ...
... The Nellcor N-20PA Handheld Pulse Oximeter ... dependability. The durable construction of the N-20PA ... extreme temperatures and conditions it has ... It is conveniently portable for spot check ...
Medicine Products: